10/17/2023 Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer
02/26/2023 bioRxiv: Cyclic peptide structure prediction and design using AlphaFold
09/06/2022 IPD spinout Vilya computing new paths to oral macrocycle therapies
08/30/2022 Fierce Biotech: Arch builds bridge to new class of medicines, leading $50M investment in the AI-enabled Vilya
08/29/2022 Vilya launches to design a new transformational class of medicines that precisely target disease biology
08/29/2022 CELL: Accurate de novo design of membrane-traversing macrocycles
08/29/2022 UW Institute for Protein Design: Design of membrane-traversing peptides leads to new spinout
08/29/2022 David Baker’s lab and ARCH sprout Lord of the Rings-inspired macrocycle biotech
08/29/2022 Timmerman Report: Arch bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
08/29/2022 GeekWire: Sneaky synthetic molecules open the way for new types of drugs and a new startup
COMPUTE BEYOND NATURE
© 2023 Vilya, Inc. All Rights Reserved.
